Literature DB >> 25044534

Discovery of natural products possessing selective eukaryotic readthrough activity: 3-epi-deoxynegamycin and its leucine adduct.

Akihiro Taguchi1, Keisuke Hamada, Masaya Kotake, Masataka Shiozuka, Hidemasa Nakaminami, Thanigaimalai Pillaiyar, Kentaro Takayama, Fumika Yakushiji, Norihisa Noguchi, Takeo Usui, Ryoichi Matsuda, Yoshio Hayashi.   

Abstract

Herein we report the first discovery of natural readthrough products that do not display antimicrobial activity. Two natural negamycins, 3-epi-deoxynegamycin and its leucine adduct, isolated 37 years ago, were found to be potent readthrough agents against nonsense mutations of eukaryotes, but not prokaryotes, without displaying antimicrobial activity. These results suggest that the compounds are valuable leads for the development of readthrough drugs against nonsense-mediated genetic diseases without the potential for contributing to the emergence of drug-resistant bacteria.
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  (+)-negamycin; natural products; nonsense mutations; peptides; readthrough activity

Mesh：

Substances：

Year:  2014        PMID： 25044534     DOI： 10.1002/cmdc.201402208

Source DB:  PubMed          Journal:  ChemMedChem        ISSN： 1860-7179            Impact factor:   3.466


  8 in total

Review 1.  Chemotherapeutics overcoming nonsense mutation-associated genetic diseases: medicinal chemistry of negamycin.

Authors:  Akihiro Taguchi; Keisuke Hamada; Yoshio Hayashi
Journal:  J Antibiot (Tokyo)       Date:  2017-09-27       Impact factor: 2.649

2.  Structural biology: Ribosome revelations.

Authors:  Nelson B Olivier
Journal:  Nature       Date:  2014-09-10       Impact factor: 49.962

Review 3.  Small molecules as therapeutic agents for inborn errors of metabolism.

Authors:  Leslie Matalonga; Laura Gort; Antonia Ribes
Journal:  J Inherit Metab Dis       Date:  2016-12-13       Impact factor: 4.982

4.  Structure-Activity Relationship Studies of 3-epi-Deoxynegamycin Derivatives as Potent Readthrough Drug Candidates.

Authors:  Keisuke Hamada; Akihiro Taguchi; Masaya Kotake; Suguru Aita; Saori Murakami; Kentaro Takayama; Fumika Yakushiji; Yoshio Hayashi
Journal:  ACS Med Chem Lett       Date:  2015-05-11       Impact factor: 4.345

5.  Effect of Readthrough Treatment in Fibroblasts of Patients Affected by Lysosomal Diseases Caused by Premature Termination Codons.

Authors:  Leslie Matalonga; Ángela Arias; Frederic Tort; Xènia Ferrer-Cortés; Judit Garcia-Villoria; Maria Josep Coll; Laura Gort; Antonia Ribes
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

6.  Structure-Activity Relationship Study of Leucyl-3-epi-deoxynegamycin for Potent Premature Termination Codon Readthrough.

Authors:  Akihiro Taguchi; Keisuke Hamada; Masataka Shiozuka; Misaki Kobayashi; Saori Murakami; Kentaro Takayama; Atsuhiko Taniguchi; Takeo Usui; Ryoichi Matsuda; Yoshio Hayashi
Journal:  ACS Med Chem Lett       Date:  2017-09-29       Impact factor: 4.345

7.  New Negamycin-Based Potent Readthrough Derivative Effective against TGA-Type Nonsense Mutations.

Authors:  Keisuke Hamada; Noriko Omura; Akihiro Taguchi; Alireza Baradaran-Heravi; Masaya Kotake; Misaki Arai; Kentaro Takayama; Atsuhiko Taniguchi; Michel Roberge; Yoshio Hayashi
Journal:  ACS Med Chem Lett       Date:  2019-09-23       Impact factor: 4.345

8.  Chemical-Induced Read-Through at Premature Termination Codons Determined by a Rapid Dual-Fluorescence System Based on S. cerevisiae.

Authors:  Emiliano Altamura; Monica Borgatti; Alessia Finotti; Jessica Gasparello; Roberto Gambari; Mariangela Spinelli; Rosa Castaldo; Nicola Altamura
Journal:  PLoS One       Date:  2016-04-27       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.